• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

    4/29/22 4:00:00 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APM alert in real time by email

    Regulatory News:

    Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2021, and provided an update on clinical and corporate developments.

    Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented "Aptorum's operational plans remain on track. In particular, our lead projects, ALS-4 (targeting infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)) and SACT-1 (targeting neuroblastoma), have respectively completed their phase 1 clinical trials and we are working towards the commencement of the next stage of human clinical trials for further proof of concept of these 2 lead projects in the United States. We are also pleased with the progress of our other lead project, RPIDD, a liquid biopsy program targeting infectious disease diagnostics which is currently undergoing human clinical validations in Singapore. We are also excited about previously announced expanded oncology and autoimmune drug discovery programs targeting unmet mutations and novel biomarkers utilizing first-in-class drug molecules. Last but not least, we are excited about the near-future commercialization of our woman's health supplement product NativusWell® in Asia and Europe, which we hope to be followed by launch in the United States, subject to the successful completion of our registration process. Our team is currently focused on delivering the above milestones for our stakeholders and we believe 2022 will be an exciting year for the company."

    Clinical Pipeline Update and Upcoming Milestones

    In 2022, we announced a number of updates for our lead and other projects:

    -

    Our ALS-4 (a first in-class anti-virulence based small molecule drug targeting infections caused by Staphylococcus aureus, including, but not limited to Methicillin Resistant Staphylococcus Aureus ("MRSA")) Phase 1 clinical trial is completed. Dosing and clinical evaluations of the Single Ascending Dose studies ("SAD") and Multiple Ascending Dose studies ("MAD") have been completed for a total of 72 healthy subjects, no subjects were dropped from the studies and no serious adverse events observed. With the encouraging safety data, we are on track to submit an IND application to the United States Food and Drug Administration ("US FDA") this year seeking to initiate a Phase 2 clinical study to assess the safety and efficacy of ALS-4 in patients.

    -

    Our SACT-1 (a repurposed small molecule drug targeting Neuroblastoma and potentially other cancer types) Phase 1 clinical trial for assessing relative bioavailability and food effect has been completed with no serious adverse events observed. Our first patent on SACT-1 has been granted by the US Patent and Trademark Office and the US FDA has also granted an Orphan Drug Designation for SACT-1 for the treatment of neuroblastoma. We plan to hold an end of Phase 1 meeting and submit a clinical protocol to the US FDA this year to initiate a Phase 1b/2a clinical study to assess the safety and efficacy of SACT-1 in patients.

    -

    Our first patent on the molecular based rapid pathogen diagnostics liquid biopsy technology ("RPIDD") has been granted by the US Patent and Trademark Office. We started the clinical validation of our RPIDD for the diagnosis of pathogens including viruses, bacteria, fungi and parasites. We have been enrolling patients with febrile neutropenia and sepsis for our clinical validation.. Various bacteria and viruses have been detected in these patient samples, including Escherichia coli, Klebsiella pneumoniae and Herpesviridae. The data have been cross-validated by standard of care diagnostics results such as blood culture technology. RPIDD achieved high analytical sensitivity and specificity of the clinical samples respectively at both low depth (60,000 reads) and high depth (1 million reads) sequencing and further clinical validation is ongoing.

    -

    We launched our oncology and autoimmune discovery and development platform. The platform will initially focus on non-small cell lung cancer ("NSCLC") and autoimmune diseases such as lupus, rheumatoid arthritis, inflammatory bowel diseases, etc. We are currently conducting optimization for selected candidates as part of its small molecule library for major targets including, but not limited to EGFR, ALK, KRAS, p53 mutations.

    Fiscal Year End Financial Results

    Aptorum Group reported a net loss of $27.1 million in 2021, as compared to net income of $4.9 million in 2020. The net income in 2020 was mainly driven by the gain on investments in marketable securities, net of $25.2 million, while there was a loss on investments in marketable securities, net of $8.0 million in 2021.

    Research and development expenses were $10.9 million in 2021 as compared to $11.6 million in 2020. The decrease in research and development expenses in 2021 was primarily due to less sponsored research to universities in 2021, partly offset by the increase in contracted research organizations services and consultation due to the development progress of our lead projects.

    General and administrative fees were $5.4 million in 2021 as compared to $4.9 million in 2020. The increase in general and administration fees was mainly due to increase in bonus expenses to our directors, employees, external consultants and advisors. The increase is partly offset by a significant decrease in travelling expenses due to the outbreak of COVID-19.

    Legal and professional fees were $2.6 million in 2021 as compared to $2.9 million in 2020. The decrease in legal and professional fees was mainly due to less one-off professional services engaged during 2021.

    Aptorum Group reported $8.3 million of cash and restricted cash as of December 31, 2021 compared to $3.6 million as of December 31, 2020. The increase in cash and restricted cash was mainly the result of the proceeds from sales of investment securities of $20.1 million and proceeds from issuance of Class A Ordinary Shares of $4.0 million in 2021, partly offset by the cash used in operating activities of $14.7 million, net repayment of loan from related parties of $2.0 million, and loan to a related party of $3.4 million in 2021.

    About Aptorum Group

    Aptorum Group Limited (NASDAQ:APM, PARIS:APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.

    For more information about the Company, please visit www.aptorumgroup.com.

    Disclaimer and Forward-Looking Statements

    This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

    This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.

    Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

    This press release is provided "as is" without any representation or warranty of any kind.

     

    APTORUM GROUP LIMITED

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

    For Years Ended December 31, 2021 and 2020

    (Stated in U.S. Dollars)

     

     

     

    Year Ended

    December 31,

    2021

     

     

    Year Ended

    December 31,

    2020

     

     

     

     

     

     

     

     

    Revenue

     

     

     

     

     

     

    Healthcare services income

     

    $

    1,541,778

     

     

    $

    911,509

     

     

     

     

     

     

     

     

     

     

    Operating expenses

     

     

     

     

     

     

     

     

    Cost of healthcare services

     

     

    (1,459,924

    )

     

     

    (1,015,023

    )

    Research and development expenses

     

     

    (10,869,642

    )

     

     

    (11,586,923

    )

    General and administrative fees

     

     

    (5,409,302

    )

     

     

    (4,853,488

    )

    Legal and professional fees

     

     

    (2,617,834

    )

     

     

    (2,854,225

    )

    Other operating expenses

     

     

    (392,511

    )

     

     

    (877,391

    )

    Total operating expenses

     

     

    (20,749,213

    )

     

     

    (21,187,050

    )

     

     

     

     

     

     

     

     

     

    Other (loss) income, net

     

     

     

     

     

     

     

     

    (Loss) gain on investments in marketable securities, net

     

     

    (8,031,595

    )

     

     

    25,241,556

     

    Loss on investments in derivatives, net

     

     

    (4,289

    )

     

     

    (199,031

    )

    Gain on use of digital currencies

     

     

    4,918

     

     

     

    -

     

    Gain on derecognition of non-financial assets

     

     

    75,000

     

     

     

    -

     

    Interest expense, net

     

     

    (93,601

    )

     

     

    (243,628

    )

    Rental income

     

     

    -

     

     

     

    30,894

     

    Loss on disposal of subsidiaries

     

     

    (3,638

    )

     

     

    -

     

    Sundry income

     

     

    146,347

     

     

     

    365,917

     

    Total other (loss) income, net

     

     

    (7,906,858

    )

     

     

    25,195,708

     

     

     

     

     

     

     

     

     

     

    Net (loss) income

     

     

    (27,114,293

    )

     

     

    4,920,167

     

    Net loss attributable to non-controlling interests

     

     

    2,065,904

     

     

     

    2,146,687

     

    Deemed dividend related to warrants down round provision

     

     

    -

     

     

     

    (755,514

    )

     

     

     

     

     

     

     

     

     

    Net (loss) income attributable to Aptorum Group Limited

     

    $

    (25,048,389

    )

     

    $

    6,311,340

     

     

     

     

     

     

     

     

     

     

    Net (loss) income per share attributable to Aptorum Group Limited

     

     

     

     

     

     

     

     

    - Basic

     

    $

    (0.71

    )

     

    $

    0.20

     

    - Diluted

     

    $

    (0.71

    )

     

    $

    0.20

     

    Weighted-average shares outstanding

     

     

     

     

     

     

     

     

    - Basic

     

     

    35,033,970

     

     

     

    31,135,882

     

    - Diluted

     

     

    35,033,970

     

     

     

    31,534,473

     

     

     

     

     

     

     

     

     

     

    Net (loss) income

     

    $

    (27,114,293

    )

     

    $

    4,920,167

     

     

     

     

     

     

     

     

     

     

    Other comprehensive (loss) income

     

     

     

     

     

     

     

     

    Exchange differences on translation of foreign operations

     

     

    (55,315

    )

     

     

    58,848

     

    Other comprehensive (loss) income

     

     

    (55,315

    )

     

     

    58,848

     

     

     

     

     

     

     

     

     

     

    Comprehensive (loss) income

     

     

    (27,169,608

    )

     

     

    4,979,015

     

    Comprehensive loss attributable to non-controlling interests

     

     

    2,065,904

     

     

     

    2,146,687

     

    Deemed dividend related to warrants down round provision

     

     

    -

     

     

     

    (755,514

     

     

     

     

     

     

     

     

     

     

    Comprehensive (loss) income attributable to the shareholders of Aptorum Group Limited

     

     

    (25,103,704

    )

     

     

    6,370,188

     

     

    APTORUM GROUP LIMITED

    CONSOLIDATED BALANCE SHEETS

    December 31, 2021 and 2020

    (Stated in U.S. Dollars)

     

     

     

    December 31,

    2021

     

     

    December 31,

    2020

     

    ASSETS

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash

     

    $

    8,131,217

     

     

    $

    3,495,231

     

    Restricted cash

     

     

    130,270

     

     

     

    130,125

     

    Digital currencies

     

     

    -

     

     

     

    1,539

     

    Accounts receivable

     

     

    78,722

     

     

     

    62,221

     

    Inventories

     

     

    35,775

     

     

     

    39,133

     

    Marketable securities, at fair value

     

     

    236,615

     

     

     

    28,384,944

     

    Investments in derivatives

     

     

    -

     

     

     

    4,289

     

    Amounts due from related parties

     

     

    47,754

     

     

     

    -

     

    Due from brokers

     

     

    76,380

     

     

     

    160,337

     

    Loan receivable from a related party

     

     

    3,358,089

     

     

     

     

     

    Other receivables and prepayments

     

     

    593,478

     

     

     

    1,378,996

     

    Total current assets

     

     

    12,688,300

     

     

     

    33,656,815

     

    Property, plant and equipment, net

     

     

    3,731,116

     

     

     

    4,686,323

     

    Operating lease right-of-use assets

     

     

    154,439

     

     

     

    547,389

     

    Long-term investments

     

     

    4,156,907

     

     

     

    4,079,707

     

    Intangible assets, net

     

     

    880,256

     

     

     

    964,857

     

    Long-term deposits

     

     

    296,225

     

     

     

    296,225

     

    Total Assets

     

    $

    21,907,243

     

     

    $

    44,231,316

     

     

     

     

     

     

     

     

     

     

    LIABILITIES AND EQUITY

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    LIABILITIES

     

     

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

     

     

    Amounts due to related parties

     

    $

    11,389

     

     

    $

    145,926

     

    Accounts payable and accrued expenses

     

     

    4,172,565

     

     

     

    3,240,772

     

    Finance lease liabilities current

     

     

    47,923

     

     

     

    49,396

     

    Operating lease liabilities, current

     

     

    145,391

     

     

     

    432,600

     

    Total current liabilities

     

     

    4,377,268

     

     

     

    3,868,694

     

    Finance lease liabilities, non-current

     

     

    -

     

     

     

    47,923

     

    Operating lease liabilities, non-current

     

     

    23,853

     

     

     

    155,121

     

    Loan payables to related parties

     

     

    -

     

     

     

    2,007,285

     

    Total Liabilities

     

    $

    4,401,121

     

     

    $

    6,079,023

     

     

     

     

     

     

     

     

     

     

    Commitments and contingencies

     

     

    -

     

     

     

    -

     

     

     

     

     

     

     

     

     

     

    EQUITY

     

     

     

     

     

     

     

     

    Class A Ordinary Shares ($1.00 par value; 60,000,000 shares authorized, 13,202,408 and 11,584,324 shares issued and outstanding as of December 31, 2021 and 2020, respectively)

     

    $

    13,202,408

     

     

    $

    11,584,324

     

    Class B Ordinary Shares ($1.00 par value; 40,000,000 shares authorized, 22,437,754 shares issued and outstanding as of December 31, 2021 and 2020)

     

     

    22,437,754

     

     

     

    22,437,754

     

    Additional paid-in capital

     

     

    43,506,717

     

     

     

    38,247,903

     

    Accumulated other comprehensive (loss) income

     

     

    (2,019

    )

     

     

    53,296

     

    Accumulated deficit

     

     

    (55,537,515

    )

     

     

    (30,489,126

    )

    Total equity attributable to the shareholders of Aptorum Group Limited

     

     

    23,607,345

     

     

     

    41,834,151

     

    Non-controlling interests

     

     

    (6,101,223

    )

     

     

    (3,681,858

    )

    Total equity

     

     

    17,506,122

     

     

     

    38,152,293

     

    Total Liabilities and Equity

     

    $

    21,907,243

     

     

    $

    44,231,316

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220429005629/en/

    Get the next $APM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

      Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until 14 October 2025, to regain compliance with the continued listing requirements. During this period, Aptorum Group Limited intends to evaluate all available options to restore

      4/16/25 12:27:42 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

      NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the "Ordinary Shares") in a registered direct offering. The ordinary shares are being sold at an offering price of $2.00 per share. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $3.0 million before deducting the placement agent's fees

      1/2/25 10:55:05 AM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

      Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. "Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board ha

      12/20/24 4:00:00 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APM
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aptorum Group Limited

      SCHEDULE 13G/A - Aptorum Group Ltd (0001734005) (Subject)

      5/15/25 7:10:38 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Aptorum Group Limited

      20-F - Aptorum Group Ltd (0001734005) (Filer)

      4/30/25 4:34:57 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Aptorum Group Limited

      6-K - Aptorum Group Ltd (0001734005) (Filer)

      4/16/25 4:01:12 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APM
    Financials

    Live finance-specific insights

    See more
    • Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

      Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. "Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board ha

      12/20/24 4:00:00 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

      Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing

      12/22/23 4:30:00 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (NASDAQ:APM, PARIS:APM) and ASP Isotopes Inc. (NASDAQ:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aptorum Group Limited (NASDAQ:APM): https://www.aptoruminfo.com/interview_accessASP Isotopes Inc. (NASDAQ:ASPI): https://aspiinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years

      3/17/23 8:15:00 AM ET
      $APM
      $ASPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Chemicals
      Industrials

    $APM
    Leadership Updates

    Live Leadership Updates

    See more
    • Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

      Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office until the third annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP as the Company's independent auditors

      12/21/23 4:30:00 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

      Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2022 annual general meeting of shareholders, which was held on December 21, 2022, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all seven directors to hold office until the next annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP (formerly know

      12/22/22 8:00:00 AM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

      Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced the results of its 2021 annual general meeting of shareholders, which was held on December 2, 2021, in Hong Kong. At the annual general meeting, the required number of shareholders of the Company: Re-elected all of the Company's current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst, Dr. Mirko Scherer, Professor Justin Wu and Professor Douglas Arner as directors of the Company until the Company's next annual general meeting o

      12/3/21 8:00:00 AM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Aptorum Group Limited (Amendment)

      SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

      4/16/24 4:32:40 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aptorum Group Limited (Amendment)

      SC 13G/A - Aptorum Group Ltd (0001734005) (Subject)

      2/2/24 4:02:58 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptorum Group Limited (Amendment)

      SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

      5/24/23 9:00:21 AM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care